EKSO Quote, Financials, Valuation and Earnings

Quantum-Si has a net margin of -85.66% compared to Ekso Bionics Holdings's net margin of -2778.61%. Ekso Bionics Holdings's return on equity of -81.29% beat Quantum-Si's return on equity of -42.63%.

Ekso Bionics Holdings has a consensus price target of $2.50, signalling upside risk potential of 453.1%. On the other hand Quantum-Si has an analysts' consensus of $3.38 which suggests that it could grow by 122.59%. Given that Ekso Bionics Holdings has higher upside potential than Quantum-Si, analysts believe Ekso Bionics Holdings is more attractive than Quantum-Si.

Ekso Bionics Holdings has a beta of 1.094, which suggesting that the stock is 9.368% more volatile than S&P 500. In comparison Quantum-Si has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ekso Bionics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quantum-Si offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ekso Bionics Holdings pays -- of its earnings as a dividend. Quantum-Si pays out -- of its earnings as a dividend.

Ekso Bionics Holdings quarterly revenues are $3.4M, which are larger than Quantum-Si quarterly revenues of $1.2M. Ekso Bionics Holdings's net income of -$2.9M is higher than Quantum-Si's net income of -$33.1M. Notably, Ekso Bionics Holdings's price-to-earnings ratio is -- while Quantum-Si's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ekso Bionics Holdings is 0.57x versus 71.18x for Quantum-Si. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -85.66% compared to Ekso Bionics Holdings's net margin of -1226.82%. Ekso Bionics Holdings's return on equity of -81.29% beat VolitionRX's return on equity of --.

Ekso Bionics Holdings has a consensus price target of $2.50, signalling upside risk potential of 453.1%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 521.34%. Given that VolitionRX has higher upside potential than Ekso Bionics Holdings, analysts believe VolitionRX is more attractive than Ekso Bionics Holdings.

Ekso Bionics Holdings has a beta of 1.094, which suggesting that the stock is 9.368% more volatile than S&P 500. In comparison VolitionRX has a beta of 0.997, suggesting its less volatile than the S&P 500 by 0.339%.

Ekso Bionics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ekso Bionics Holdings pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Ekso Bionics Holdings quarterly revenues are $3.4M, which are larger than VolitionRX quarterly revenues of $474.5K. Ekso Bionics Holdings's net income of -$2.9M is higher than VolitionRX's net income of -$5.8M. Notably, Ekso Bionics Holdings's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ekso Bionics Holdings is 0.57x versus 33.01x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -85.66% compared to Ekso Bionics Holdings's net margin of -4291.67%. Ekso Bionics Holdings's return on equity of -81.29% beat Catheter Precision's return on equity of -65.84%.

Ekso Bionics Holdings has a consensus price target of $2.50, signalling upside risk potential of 453.1%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 551.47%. Given that Catheter Precision has higher upside potential than Ekso Bionics Holdings, analysts believe Catheter Precision is more attractive than Ekso Bionics Holdings.

Ekso Bionics Holdings has a beta of 1.094, which suggesting that the stock is 9.368% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.870, suggesting its less volatile than the S&P 500 by 187.02%.

Ekso Bionics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ekso Bionics Holdings pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Ekso Bionics Holdings quarterly revenues are $3.4M, which are larger than Catheter Precision quarterly revenues of $96K. Ekso Bionics Holdings's net income of -$2.9M is higher than Catheter Precision's net income of -$4.1M. Notably, Ekso Bionics Holdings's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ekso Bionics Holdings is 0.57x versus 2.11x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -85.66% compared to Ekso Bionics Holdings's net margin of -10.04%. Ekso Bionics Holdings's return on equity of -81.29% beat Xtant Medical Holdings's return on equity of -35.34%.

Ekso Bionics Holdings has a consensus price target of $2.50, signalling upside risk potential of 453.1%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 193.33%. Given that Ekso Bionics Holdings has higher upside potential than Xtant Medical Holdings, analysts believe Ekso Bionics Holdings is more attractive than Xtant Medical Holdings.

Ekso Bionics Holdings has a beta of 1.094, which suggesting that the stock is 9.368% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

Ekso Bionics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ekso Bionics Holdings pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Ekso Bionics Holdings quarterly revenues are $3.4M, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Ekso Bionics Holdings's net income of -$2.9M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Ekso Bionics Holdings's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ekso Bionics Holdings is 0.57x versus 0.68x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.